Press Releases

Biothera to Present Three Abstracts at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

EAGAN, MN — November 2, 2015 — Biothera, a clinical stage biotechnology company pioneering the development of immune potentiators known as PAMPs for cancer immunotherapy, will present three abstracts at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place November 5–9 at the Hynes Convention Center in Boston. PAMPs (Pathogen Associated Molecular Patterns) serve as critical recognition signals...

Read More


Kerry Acquires Wellmune® from Biothera Inc.

Tralee, Ireland and Eagan, Minnesota, U.S.A. ─ October 21, 2015 ─ Kerry Group plc, the global taste and nutrition company, has acquired Wellmune® from Biothera Inc., a natural food, beverage and supplement ingredient that is clinically proven to help strengthen the immune system. “At Kerry, cutting-edge science and technology informs everything we help shape and create. The addition of Wellmune to our portfolio offers Kerry...

Read More


Biothera Appoints Dr. Jose Iglesias as Chief Medical Officer

EAGAN, MN — October 15, 2015 — Biothera Pharmaceuticals, Inc., today announced the appointment of Jose Iglesias, M.D., as Chief Medical Officer. Dr. Iglesias will be responsible for clinical development, medical affairs, and other functions related to the advancement of Imprime PGG, the company’s cancer immunotherapy currently in multiple mid- and late-stage clinical testing. Imprime PGG is a novel, proprietary compound known as a pathogen-associated...

Read More


Biothera’s Cancer Immunotherapy Drug Imprime PGG Elicits Increased Natural Killer Cell Activation and Cancer Cell Killing

Study Further Demonstrates Imprime’s Effect in Enlisting the Innate Immune System to Eradicate Cancer NEW YORK – Sept. 18, 2015 – Imprime PGG, Biothera’s late-stage investigational cancer immunotherapy drug, enhances the tumor killing function of the innate immune system’s Natural Killer (NK) cells, according to research presented today at Inaugural International Cancer Immunotherapy Conference jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the...

Read More


Biothera’s Imprime PGG Cancer Immunotherapy Drug Activates Dendritic Cells, Leading to Enhanced T Cell Expansion and Cytokine Production

Imprime PGG, as a PAMP, effectively activates antigen presentation and drives T cell engagement NEW YORK – Sept. 18, 2015 – New data reported today at the Inaugural International Cancer Immunotherapy Conference, jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research, demonstrate that Biothera’s investigational cancer immunotherapy drug Imprime PGG enhances...

Read More


Imprime PGG Specifically Enhances the Potent Tumor Killing Activity of Neutrophils

Imprime PGG treatment enables neutrophils to kill cancer cells decorated with therapeutic monoclonal antibody NEW YORK – Sept. 16, 2015 – Research presented today by Biothera shows for the first time that cancer cells coated with therapeutic monoclonal antibodies are specifically recognized and killed by Imprime PGG-treated neutrophils. The findings were reported at the Inaugural International Cancer Immunotherapy Conference, jointly sponsored by the Cancer Research Institute, the...

Read More


Biothera’s Imprime PGG Enhances Anti-Tumor Activity of the Innate Immune System’s Macrophages

Research examines Imprime PGG’s effect on macrophages in engulfing human cancer cells NEW YORK – Sept. 16, 2015 – Research presented today at the Inaugural International Cancer Immunotherapy Conference, jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research, demonstrates that Biothera’s cancer immunotherapy drug, Imprime PGG, enhances the anti-tumor activity of...

Read More


Biothera Reports Additional Biomarker Data for Predicting Response to Its Investigational Cancer Immunotherapy Drug

A genetic variant may reveal patients with the greatest likelihood for response to Imprime PGG- based therapy NEW YORK – Sept. 16, 2015 – Biothera today will present research at the Inaugural International Cancer Immunotherapy Conference, jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research, advancing the patient selection biomarker strategy...

Read More


Biothera to Present New Data at International Cancer Immunotherapy Conference

EAGAN, MN — September 1, 2015 — Biothera will present new data to cancer researchers from around the world that expands scientific understanding of how the company’s investigational cancer immunotherapy Imprime PGG® engages both the innate and adaptive immune systems to kill antibody-targeted cancer cells. Biothera has had five research abstracts accepted for presentation at the International Cancer Immunotherapy Conference September 16-19 in New York...

Read More


Cancer Research UK Funding Preclinical Study with Biothera’s Imprime PGG in Combination Therapy

EAGAN, MN — August 18, 2015 — Cancer Research UK (CRUK), the world’s largest charitable funder of cancer research, will fund preclinical research evaluating the efficacy of Biothera’s investigational cancer immunotherapy Imprime PGG® in combination with monoclonal antibody (MAb) therapies as a precursor to a phase 1-2 clinical study in rituximab-refractory follicular lymphoma. The research will be conducted at the Manchester Academic Health Sciences Centre under the...

Read More



Page 3 of 612345...Last »